Anorectal fi stulas are quite common proctologic disorders. They can be either of cryptoglandular origin or can be associated with Crohn's disease and chronic ileocolitis. Mechanical obstruction and local infections are prime causes of this pathological condition. Genetic predisposition and inadequate immune response with overproduction of pro-infl ammatory cytokines appear prominently in the course of Crohn's disease. Interferon-γ, a Th1 type cytokine, refl ecting the engagement of cellular immune mechanisms, is the fi rst to be produced in the intestinal mucosa. The infl ammatory process in the colon mucosa induced by the abundant microbial fl ora is sustained and turned chronic by the gradual elevation of the local TNF-α and regulatory cytokines levels (interleukin-10, transforming growth factor-β). The number of activated local memory T cells CD4+CD45RB lo increases signifi cantly. The regulatory CD4+CD25+ Т lymphocytes producing interleukin-10 increase also trying to counterbalance the cytokine reaction. The chronic infl ammatory infi ltrates of the colon mucosa are represented by lymphocytes, plasma cells, macrophages. The long-term activation of macrophages by the released interferon-γ leads to tissue damage and potentiation of angiogenesis -a risk factor for carcinoma development. Management of anorectal abscesses and fi stulas is complex aiming to alleviate the symptoms, prevent relapses, reduce the risk of sphincter damage and improve quality of life. The main approach (surgery) should be combined with antimicrobial infection control and immunomodulation by intravenous or local administration of anti-TNF-α antibodies.
INTRODUCTION
Anorectal fi stulas (ARF) are among the most common benign proctologic diseases. Their prevalence as non-specifi c cryptoglandular ARF is between 8.6 and 18.4 per 100000 people per year, while as associated clinical manifestation they are found in 14-43% of Crohn's disease patients and in as much as 76% of all patients with infl ammatory diseases of the ileocolon. [1] [2] [3] According to the cryptoglandular theory proposed by Prat and Eisehammer, in their former form, ARF are considered a chronic phase in the development of pathologic infl ammatory abscesses in the anal glands in humans. 2 Their mechanical obstruction and local infection are main pathogenetic mechanisms in the occurrence and development of ARF. 3 In a similar way they are accepted as consequence of anorectal abscess (ARA), being along with the ulcerations of colon mucosa and strictures the main complications of Crohn's disease. [4] [5] [6] The clinical manifestations of frequently recurring and fi stulizing anorectal disease lead to anal incontinence with poor hygiene and overall decreased quality of life. 7 Nowadays, Crohn's disease is considered a chronic granulomatous disease of the intestines in which the intestinal wall is thickened and infl ammatory altered as a result of the genetic predisposition and development of immune response to infectious agents. 8 The basis of the process is the immune reaction, presenting with overproduction of pro-infl ammatory cytokines further deteriorating the intestinal lesions typical for the disease. 9 6 10 The classical view on the problem is that there is much greater probability of recurrence of ARF in Crohn's disease due to diffi culties in the combined (medication and surgical) treatment.
CYTOKINES AS "CONDUCTORS" OF THE LO-CAL IMMUNE REACTION IN ANORECTAL FIS-TULAS
In ARF combined with Crohn's disease, the balance between pro-infl ammatory cytokines (interleukin-1 [IL-1], interleukin-6 [IL-6], interferon-gamma [IFN-γ], tumor necrosis factor-alpha [TNF-α]) and regulatory cytokines (interleukin-10 [IL-10], transforming growth factor-beta [TGF-β]), is essential for maintaining the local immunity of the intestinal mucosa. 11 Cytokines are produced from various cells. IFN-γ is synthesized by Th1 lymphocytes, conducting cell-mediated immunity and affecting activation of macrophages. Its production is dependent on TNF-α levels. 12, 13 In ARA and ARF that are concomitant complications of Crohn's disease or other forms of chronic colitis, the local overproduction of proinfl ammatory cytokines IFN-γ and TNF-α along with IL-10 and IL-12, is main pathogenetic factor that sustains the infl ammatory process in the intestinal mucosa. The abundant microbial fl ora in the terminal ileum and the colon is a powerful inducing factor for cytokine synthesis. Studies of experimental mice models show that IFN-γ is the fi rst and the most rapidly increasing cytokine preceding the infl ammatory cellular alterations in the intestinal mucosa and the activation of local lymphocytes. 4 Following the changes in IFN-γ and correlating with the severity of infl ammation, the local levels of TNF-α, IL-4, IL-5 и IL-10 are raised. The last two cytokines possess modulating effect on later stages of infl ammation. Increased local levels of IFN-γ may serve as a prognostic marker of recurrence of the disease. (Fig. 1) Cytokine concentrations are measured in in vitro fi ve-day cell culture supernatant of colon mucosa biopsies acquired by colonoscopy. 14 Enzyme-linked immunosorbent assay (ELISA) is used. Another possibility is immunohistochemical determination of cytokine levels in mononuclear cells from lamina propria. 15 Our long-term clinical and scientifi c studies in patients with various infl ammatory and infectious processes (gastrointestinal forms of salmonellosis, viral hepatitis B, Mediterranean spotted fever) convincingly show that the determination of serum and local levels of some pro-infl ammatory cytokines (IL-1, IL-6, IFN-γ TNF-α) has diagnostic and prognostic signifi cance for the development of the disease. [16] [17] [18] [19] We therefore decided that the determination of local cytokine levels from intestinal biopsy material in patients with ARF may be used for assessment of infl ammatory reaction development.
OTHER IMMUNOLOGICAL FACTORS TRIGGER-ING ANORECTAL FISTULAS
The role of T-lymphocytes in Crohn's disease as immune cells in the development of chronic infl ammatory diseases of the colon, including complicated ARF, is demonstrated by experiments on mice with chronic ileitis and perianal fi stulas. 4 Flow cytometric analysis of lymphocytes from mesenteric lymph nodes of laboratory animals shows decrease in CD4+ Т-lymphocytes with naive phenotype (CD4+CD45RB hi population), while the percentage of activated memory cells CD4+CD45RB lo , as well as of regulatory CD4+CD25+ Т-lymphocytes (T regs), expressing alpha-chain of IL-2, is signifi cantly greater. The increase of cells with activation markers and of Т regs with disease progression is a sign of occurrence of memory and activated T-cells. Activated Т regs in intestines play an important role in the control of cytokine imbalance. 14 Isolated from intestinal mucosa of animals with infl ammatory diseases of the colon, they are considered intestinal infl ammation regulators and responsible for induction of immune tolerance in the colon mucosa via IL-10 production.
Continuous infl ammatory process in ARA and ARF associated with certain microbial agents is a major factor of immune suppression in patients. Abscess etiology is polymicrobial, being associated in over 70% of the cases with obligate (Bacteroides fragilis, Peptostreptococcus spp., Prevotella spp., Fusobacterium spp. etc.) and facultative anaerobic (S. aureus, Streptococcus spp., Escherichia coli) bacteria. 13 Brook and Frazier 20 report the highest participation of Gram positive bacteria (staphylococci and streptococci), followed by E. coli among facultative anaerobes. Our previous studies show that E. coli and other gram negative bacteria are isolated in more than half of the patients with abscess forms of ARF, and gram positive bacteria (enterococci, staphylococci) account for one third of the isolated facultative anaerobes. 21 We consider the high percentage of E. coli isolated from the investigated purulent material to be a disturbing fact since, according to Hamalainen and Sainio, these cases are prone to chronifi cation with fi stulization of the process. 22 Risk of sepsis development is present in considerate share of the patients. 20 Based on the hypothesis that prolonged inflammation caused by infectious agents leads to immunosuppression, our investigations of peripheral blood from ARF patients prove functional insuffi ciency of phagocytic reaction with imbalance in NBT test, total leucocyte count and neutrophil percentage. 21 Humoral factors of systemic acquired immunity (serum immunoglobulins A, G and M) are however scarcely engaged in the abovementioned infl ammatory processes, which implies the predominant role of local immune response.
On the other hand, the overactivation of the immune system in Crohn's disease is related to the occurrence of autoimmune or allergic reactions. In 13 to 100% of the patients with Crohn's disease, including patients with ARF, perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) are 
The contact of antigen presenting cells (АPC) -dendritic cells and macrophages, with microbial antigens leads to activation of intestinal T lymphocytes in Peyer's patches and lamina propria after stimulation with IL-1. One of the T-helper subpopulations -Th1, produces IL-2 for proliferation and differentiation of T and B cells. Th1 also release IFN-γ, stimulating the activation of intestinal macrophages which begin to synthesize the pro-infl ammatory cytokines TNF-α and IL-1 with cytotoxic effect, blood vessels alterations and fever. IL-2 also stimulates other T cells -Th2, which synthesize IL-4, helping the differentiation of B lymphocytes to plasma cells which in turn produce secretory IgA. T-regulatory cells (T reg) play controlling role over the infl ammatory process in the intestinal mucosa. They produce regulatory TGF-β and IL-10. TGF-β supports the differentiation of macrophages, the secretion of extracellular matrix proteins (EMP), wound healing and tissue fi brosis. IL-10 inhibits the cell released IFN-γ and neutralizes

LOCAL IMMUNOHISTOLOGICAL ALTERATIONS IN COLON MUCOSA IN ANORECTAL FISTULAS
The morphological histological alterations in the colon mucosa of patients with Crohn's disease also provide evidence of involvement of immune mechanisms in the development of ARA and ARF as complications of infl ammatory diseases of the colon. In these cases the infl ammatory reaction is presented by mononuclear and polymorphonuclear cells in lamina propria and neutrophils in the epithelium. 25 Granulomatous alterations with polynuclear giant cells in the colon mucosa -a sign of chronic infl ammation, may be found in patients with Crohn's disease. Except for macrophages, lymphocytes and plasma cells also infi ltrate the intestinal mucosa. Prolonged activation of macrophages leads to tissue damage due to the released by them substances, one of which -nitric oxide (NO), directly damages DNA, inhibits DNA reparative enzymes, suppresses caspase activity and apoptosis, and stimulates angiogenesis. 26 The infl ammatory process generates pro-inflammatory cytokines and prostaglandins, which also potentiate angiogenesis. Cancerogenic products like reactive oxygen species are produced at the site of the chronic infl ammatory reaction. That is the reason for increased risk of carcinoma in case of prolonged infl ammatory benign alterations in the intestinal mucosa in ARA and ARF, as well as in anal fi ssures. 26, 27 These benign anorectal diseases also enhance the negative role of human papillomavirus (HPV) in cancerogenesis initiation facilitating its access to the anal epithelial cells. In allergy-associated chronic obstipation in patients with Crohn's disease the immunohistologic alterations of the rectal mucosa are presented with cubic or plasmatic metaplasia of the epithelium, infiltration with plasma cells and lymphocytes and presence of lymphoid nodules in lamina propria. 24 The fi ndings of local immune alterations in patients with ARF are supported convincingly by experiments with mice with chronic ileitis and fi stulizations. 4 The ulcerations of anal mucosa, the fi ssures near the anus and ARF in the mice are accompanied by occurrence of chronic infl ammatory infi ltrates of lymphocytes, plasma cells and macrophages in the anus and the rectum, as well as by accumulation of neutrophils in the perianal soft tissues. Loss of normal villous architecture of the intestinal mucosa and thickening (to the extent of hypertrophy) of the muscle layer of the intestinal wall from the distal to the proximal compartment of the ileum are also observed.
NOVEL COMBINED TREATMENT (SURGERY AND IMMUNOMODULATION) OF ANORECTAL FISTULAS IN CROHN'S DISEASE
The modern therapy used for ARFs, especially the type presenting as complications of Crohn's disease or chronic infl ammatory diseases of the colon, is still a challenge to surgeons and gastroenterologists, because full recovery and prevention of disease recurrence are hard to achieve while keeping a better quality of life. 25 There are two main approaches in the treatment of ARF in Crohn's disease: surgery and conservative treatment. 28, 29 (Table 1 ). The current trends demand defi nitively a combined therapy using both approaches. 30, 31 Surgery is the classical therapeutic approach in treating ARA and ARF in Crohn's disease. The goals in this approach are symptom alleviation, ARF-associated draining of ARA, reduction of disease recurrence and danger of damaging the anal sphincters by preventing the development of anal incontinence, even to the point of avoiding the need for proctectomy in some rare cases. Currently, surgical interventions in this fi eld include: opening of the fi stula tract by one-or two-stage fi stulotomy (in low ARF); seton treatment with noncutting (draining) ligatures (in higher fi stulas with involvement of considerable part of the external anal sphincter), or plastic covering of the internal fi stulous opening with endorectal forward-shifted fl ap (as an alternative to the two classical methods but possible only in patients without macroscopic signs for rectal infl ammation). 5, 32, 33 In ARF, complicated with Crohn's disease, a trend for less aggressive surgical approaches, including drainage by insertion of non-cutting setons, is promoted, since more aggressive surgical procedures increase the risk of anal incontinence. 31 For these complicated cases we agree with most of the authors and prefer to use the most novel surgical techniques for obturation of ARF by instilling fi brin glue into them to attach them, or by occlusion of the lumen by implantation of biological anal fi stula plugs, manufactured from porcine small intestinal submucosa -Surgisis ® -Anal Fistula Plug. 31, 34 The surgical treatment we have been performing for several years in patients with chronic ARF, including instilling of fi brin glues, is safe, easy to perform and effective in more than 70% of the patients, preventing development of anal incontinence and the need of additional therapy. 35, 36 Drug therapy in perianal fi stulas in Crohn's disease includes: 1. standard medications, including immunomodulators; 2. hyperbaric oxygen therapy and 3. anti-TNF-α antibodies.
The drug typically used here are: oral 5-aminosalycilates; antimicrobial drugs (metronidazole, ciprofl oxacin); corticosteroids for systemic and topical application (prednisone and beclometasone dipropionate), and immunomodulators (azathiоprine, cyclosporinе, 6-mercaptopurine, methotrexate, tacrolimus). 37 Despite their application, the relapses of ARF are quite frequent and the fi stulas are diffi cult to heal. Furthermore, the immunomodulators applied in these cases have serious side effects such as pancreatitis, hepatitis and severe leucopenias. Hyperbaric oxygen therapy is still not widely accepted alternative method. It is applied in patients with severe perianal complications of Crohn's disease. The therapy's mechanism of action is growth suppression of anaerobic microorganisms which in addition to inducing local infl ammation leads to ARA with development of ARF. It is carried out in series of hyperbaric pressure of 2.5 atm for 20 to 90 min, accompanied by local administration of 100% oxygen. 38 The interest in investigating the cytokine imbalance in the intestinal mucosa in infl ammatory intestinal diseases does not subside due to the appealing possibility that pro-infl ammatory mediators are neutralized through proper therapy. Therapeutical approaches are focused on application of anti-infl ammatory molecules. The need for such an approach is determined by the fact that complicated ARA and ARF in Crohn's disease may not be always successfully treated with surgical interventions because of risk of anal incontinence.
Candidates in the modern strategy for modulation of the inadequate immune response in Crohn's disease are two biological drugs: 1. humanized chymeric antibody against TNF-α (infl iximab) and 2. human anti-TNF-α antibody (adalimumab). 39, 40 The application of TNF-antagonists from the mid-90's of the last century is a novelty in the treatment of Crohn's disease and ulcerative colitis, especially in patients who are resistant to therapy with conventional medications like corticosteroids and immunomodulators. Infl iximab has local mechanism of action on the intestinal mucosa, related with neutralization of TNF-α. 41 The antibody suppresses also the quantity of T-cells, producing TNF-α cytokine in lamina propria by stimulation of their apoptosis and reduction of IFN-γ production by intestinal T-cells. 14 The reduced cytokine production after the treatment correlates with clinical improvement in about half of the patients -remission of the disease or even healing of the fi stulas.
Treatment with Infl iximab in Crohn's disease is conducted either by intravenous infusions or by local injections. Venous infusions are three times daily in a dose of 5 mg/kg for 2 hours, at certain intervals -most often at 0, 2 and 6 weeks. 14, 42, 43 Application of prolonged infusions (for more than 40 weeks) is possible. In case of systemic therapy with infl iximab the following side effects may be observed [44] [45] [46] [47] :
• autoimmune reactions -appearance of antinuclear antibodies or antibodies against infl iximab in 7-10% of patients; • anaphylactic and delayed type hypersensitivity reactions in repeated application in 20% of patients; • infectious complications -reactivation of tuberculosis and pulmonary infections; • appearance of carcinomas or lymphomas.
Local injections are applied in the treatment of non-complicated ARF in Crohn's disease. 28, 48 Infl iximab in a dose of 20 mg dissolved in 10 ml saline is injected in the primary fi stula tract and around the external fi stulous opening. The procedure is preceded from application of anesthetic drug (5 ml lidocain in 3 ml 8.4% bicarbonate solution). Three to fi ve injections of infl iximab are applied each week until the secretion entirely discontinues. 28 The effect is considered positive if reduction or total cease of fi stula secretion for at least 4 weeks is achieved. External perineal fi stulas are better treated by topical application in comparison to the internal (recto-vaginal and entero-vesical) ones. 28, 49 The local treatment with infl iximab solution is believed to prevent the side-effects observed in systemic infusions.
Adalimumab is applied in dosage of 80 or 160 mg weekly at the beginning of the therapy and 40 or 80 mg after the second week. It is followed by supportive treatment with 40 mg every second week. 37 Studies of patients with fi stulizing Crohn's disease show good effect of the medication in achieving remission. 50, 51 Generally, TNF antagonists stimulate ARF healing, increase the effectiveness of surgical intervention and reduce the risks associated with it.
CONCLUSIONS
Anorectal abscesses and fi stulas are frequent complications of cryptoglandular disease and Crohn's disease or chronic infl ammatory bowel disease. The etiology and pathogenesis of their occurrence and development, as well as of the diseases associated with them, are not quite clear. The prolonged infl ammation of the colon wall causes local hyperproduction of pro-infl ammatory and regulatory cytokines. The intestinal infl ammation is controlled locally by a special population of regulatory T-cells. The histological alterations in the intestinal mucosa are represented by macrophages, lymphocytes and plasma cells. By presenting the main immuno-pathogenic mechanisms playing important role in the development of the infl ammatory process in these diseases, we would like to underline the necessity of complex therapeutic approach in ARF, especially for those associated with Crohn's disease. This approach is concurrent with the modern trends for combined therapy -surgical treatment, antimicrobial control of infection and immunomodulation. Most of the research show rather encouraging results in using anti-TNF-α antibodies.
